Afatinib combined with anti-PD1 enhances immunotherapy of hepatocellular carcinoma via ERBB2/STAT3/PD-L1 signaling.

Chao Yu,Xinyi Zhang,Min Wang,Gaoxin Xu,Siqi Zhao,Yongheng Feng,Chao Pan,Weijun Yang,Jin Zhou,Longcheng Shang,Yong Ma

Frontiers in oncology（2023）

引用 1|浏览0

暂无评分

摘要

Afatinib enhances PD-L1 expression in tumor cells through the STAT3/PD-L1 pathway. The combination of afatinib and anti-PD1 treatment significantly increases the immunotherapeutic effect of HCC.

查看译文

关键词

hepatocellular carcinoma,afatinib,immunotherapy,erbb2/stat3/pd-l1

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要